Skip to main content
. 2022 Mar 24;8(1):e31388. doi: 10.2196/31388

Table 1.

Search strategies for identification of tweets related to pancreatic cancer and further categorization into 5 domains: prevention, survivorship, treatment, research, and policy.

Search term Keywords, combinations, and phrases
Pancreatic cancer (
pancchat OR pancan OR pancreaticcancer* OR pancreascancer* OR WorldPancreaticCancerDay OR #WPCD


OR ((pancreatic OR Pancreas OR pancpath OR acinar OR vipoma OR somatostatinoma OR glucagonoma OR insulinoma OR gastrinoma OR pseudopapillary) AND (cancer OR adenocarcinoma OR carcinoma OR malignant OR tumor OR tumour))


OR ((PDAC OR PancNET OR PNET) AND (pancreatic OR Pancreas OR pancpath OR cancer OR tumor OR tumour OR mutated OR metastatic))


OR ((pancreatic OR Pancreas OR pancpath OR acinar OR vipoma OR somatostatinoma OR glucagonoma OR insulinoma OR gastrinoma OR pseudopapillary OR PDAC OR PancNET OR PNET) AND (gemcitabine OR paclitaxel OR FOLFIRI OR mFOLFIRI OR FOLFOX OR fluorouracil OR 5FU OR irintecan OR irinotecan OR everolimus OR evorolimus OR oxaliplatin OR cisplatin OR “demplatin pegraglumer” OR capacitabine OR capecitabine OR docetaxel OR carboplatin OR glufosfamide OR glucosphamide OR leucovorin OR folinic OR tetrahydrofolic OR pembralizumab OR pembrolizumab OR nivolumab OR ipulimumab OR ipalimumab OR ipilimumab OR ipilumab OR cabiralizumab OR cabaralizumab OR cabarilizumab OR urelumab OR olaratumab OR talabostat OR cobimetanib OR cobimetinib OR anetumab OR epacadostat OR atezolizumab OR pamrevlumab OR pegilodecakin OR PEGylated OR PEGPH20 OR pegvorhyaluronidase OR avelumab OR bempegaldesleukin OR erlotinib OR sunitinib OR olaparib OR rucaparib OR napabucasin OR masican OR masitinib OR velaparib OR veliparib OR GVAX OR CRS207 OR Gemzar OR infugem OR onxol OR taxol OR abraxane OR adrucil OR efudex OR efudix OR carac OR onivyde OR campto OR afinitor OR zortress OR eloxatin OR platinol))
)


AND site:twitter.com

Prevention prevent* OR screen OR screening OR ((reduce OR decrease OR lower OR limit) NEAR/3 (risk))
Survivorship survivor* OR survival OR “OS” OR “PFS” OR overcome OR beat
Treatment treat OR treatment* OR treating OR gemcitabine OR paclitaxel OR “nab-paclitaxel” OR FOLFIRI* OR mFOLFIRI*,…….
Research Research OR study OR trial OR trials OR studies OR data
Policy policy OR policymak* OR ((NIH or NCI)) AND (fund*)) OR (insurance AND expan*)